SAFETY DATA SHEET

Orbifloxacin Liquid Formulation

Version 3.3  Revision Date: 01.10.2020  SDS Number: 785435-00011  Date of last issue: 13.09.2019
Date of first issue: 28.06.2016

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name: Orbifloxacin Liquid Formulation

Manufacturer or supplier's details
Company name of supplier: MSD
Address: 2000 Galloping Hill Road
Kenilworth - New Jersey - U.S.A. - 07033
Telephone: 908-740-4000
Emergency telephone: 1-908-423-6000
E-mail address: EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use
Recommended use: Veterinary product

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification
Reproductive toxicity: Category 2
Specific target organ toxicity - repeated exposure (Oral): Category 2 (Eye)

GHS label elements
Hazard pictograms:

Signal Word: Warning
Hazard Statements: H361d Suspected of damaging the unborn child.
H373 May cause damage to organs (Eye) through prolonged or repeated exposure if swallowed.

Precautionary Statements
Prevention:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe mist or vapors.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:
P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents/ container to an approved waste disposal plant.
SAFETY DATA SHEET
Orbifloxacin Liquid Formulation

Other hazards
None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Orbifloxacin</td>
<td>113617-63-3</td>
<td>&gt;= 1 &lt; 5</td>
</tr>
<tr>
<td>Lactic acid</td>
<td>50-21-5</td>
<td>&gt;= 1 &lt; 3</td>
</tr>
<tr>
<td>Sodium hydroxide</td>
<td>1310-73-2</td>
<td>&gt;= 1 - &lt; 2</td>
</tr>
</tbody>
</table>

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air. Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure if swallowed.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during firefighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Metal oxides
Specific extinguishing methods:
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for fire-fighters:
In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures:
Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions:
Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g., by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up:
Soak up with inert absorbent material.
For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures:
See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation:
Use only with adequate ventilation.

Advice on safe handling:
Do not breathe mist or vapors.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures:
If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working area.
When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage:
- Keep in properly labeled containers.
- Store locked up.
- Store in accordance with the particular national regulations.

Materials to avoid:
- Do not store with the following product types:
  - Strong oxidizing agents

**SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**

### Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Orbifloxacin</td>
<td>113617-63-3</td>
<td>TWA</td>
<td>0.2 mg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Sodium hydroxide</td>
<td>1310-73-2</td>
<td>VLE-P</td>
<td>2 mg/m³</td>
<td>NOM-010-STPS-2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C</td>
<td>2 mg/m³</td>
<td>ACGIH</td>
</tr>
</tbody>
</table>

**Engineering measures**
- Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
- All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
- Laboratory operations do not require special containment.

**Personal protective equipment**

**Respiratory protection**
- If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Filter type: Combined particulates and organic vapor type

**Hand protection material**
- Chemical-resistant gloves

**Eye protection**
- Wear safety glasses with side shields or goggles.
- If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
- Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin and body protection**
- Work uniform or laboratory coat.

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

**Appearance**
- Suspension
<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Color</td>
<td>light brown</td>
</tr>
<tr>
<td>Odor</td>
<td>odorless</td>
</tr>
<tr>
<td>Odor Threshold</td>
<td>No data available</td>
</tr>
<tr>
<td>pH</td>
<td>No data available</td>
</tr>
<tr>
<td>Melting point/freezing point</td>
<td>No data available</td>
</tr>
<tr>
<td>Initial boiling point and boiling range</td>
<td>No data available</td>
</tr>
<tr>
<td>Flash point</td>
<td>No data available</td>
</tr>
<tr>
<td>Evaporation rate</td>
<td>No data available</td>
</tr>
<tr>
<td>Flammability (solid, gas)</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Flammability (liquids)</td>
<td>No data available</td>
</tr>
<tr>
<td>Upper explosion limit / Upper flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Lower explosion limit / Lower flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Vapor pressure</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative vapor density</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative density</td>
<td>No data available</td>
</tr>
<tr>
<td>Density</td>
<td>No data available</td>
</tr>
<tr>
<td>Solubility(ies)</td>
<td></td>
</tr>
<tr>
<td>Water solubility</td>
<td>No data available</td>
</tr>
<tr>
<td>Partition coefficient: n-octanol/water</td>
<td>No data available</td>
</tr>
<tr>
<td>Autoignition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Decomposition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Viscosity</td>
<td></td>
</tr>
<tr>
<td>Viscosity, kinematic</td>
<td>No data available</td>
</tr>
<tr>
<td>Explosive properties</td>
<td>Not explosive</td>
</tr>
<tr>
<td>Oxidizing properties</td>
<td>The substance or mixture is not classified as oxidizing.</td>
</tr>
<tr>
<td>Molecular weight</td>
<td>No data available</td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET
Orbifloxacin Liquid Formulation

SECTION 10. STABILITY AND REACTIVITY

Reactivity: Not classified as a reactivity hazard.
Chemical stability: Stable under normal conditions.
Possibility of hazardous reactions: Can react with strong oxidizing agents.
Conditions to avoid: None known.
Incompatible materials: Oxidizing agents
Hazardous decomposition products: No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure
Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Product:
Acute oral toxicity: Acute toxicity estimate: > 5,000 mg/kg
Method: Calculation method

Components:
Orbifloxacin:
Acute oral toxicity: LD50 (Rat): > 3,000 mg/kg
Remarks: No mortality observed at this dose.
LD50 (Mouse): > 2,000 mg/kg
Remarks: No mortality observed at this dose.
LD50 (Dog): > 600 mg/kg
Symptoms: Vomiting
Remarks: No mortality observed at this dose.

Acute inhalation toxicity: Remarks: No data available

Acute dermal toxicity: Remarks: No data available

Acute toxicity (other routes of administration): LD50 (Rat): > 200 mg/kg
Application Route: Intramuscular
LD50 (Mouse): 500 mg/kg
Application Route: Intramuscular
LD50 (Rat): 233 mg/kg
Application Route: Intravenous

Particle size: No data available
**Lactic acid:**
- **Acute oral toxicity**: LD50 (Rat): > 2,000 mg/kg  
  Remarks: Based on data from similar materials
- **Acute inhalation toxicity**: LC50 (Rat): > 5 mg/l  
  Exposure time: 4 h  
  Test atmosphere: dust/mist  
  Method: OECD Test Guideline 403  
  Remarks: Based on data from similar materials
- **Acute dermal toxicity**: LD50 (Rabbit): > 2,000 mg/kg  
  Assessment: The substance or mixture has no acute dermal toxicity  
  Remarks: Based on data from similar materials

**Sodium hydroxide:**
- **Acute inhalation toxicity**: Assessment: Corrosive to the respiratory tract.

**Skin corrosion/irritation**
Not classified based on available information.

**Product:**
- **Species**: Rabbit  
  **Result**: No skin irritation

**Components:**

**Orbifloxacin:**
- **Species**: Rabbit  
  **Method**: Draize Test  
  **Result**: No skin irritation

**Lactic acid:**
- **Species**: Rabbit  
  **Result**: Skin irritation  
  **Remarks**: Based on data from similar materials

**Sodium hydroxide:**
- **Result**: Corrosive after 3 minutes or less of exposure

**Serious eye damage/eye irritation**
Not classified based on available information.

**Product:**
- **Species**: Rabbit  
  **Result**: Mild eye irritation
Components:

Orbifloxacin:
Species: Rabbit
Result: Mild eye irritation
Method: Draize Test

Lactic acid:
Species: Chicken eye
Remarks: Based on data from similar materials
Result: Irreversible effects on the eye

Sodium hydroxide:
Result: Irreversible effects on the eye
Remarks: Based on skin corrosivity.

Respiratory or skin sensitization

Skin sensitization
Not classified based on available information.

Respiratory sensitization
Not classified based on available information.

Product:
Test Type: Magnusson-Kligman-Test
Routes of exposure: Dermal
Species: Guinea pig
Result: Not a skin sensitizer.

Components:

Orbifloxacin:
Test Type: Maximization Test
Routes of exposure: Dermal
Species: Guinea pig
Result: Not a skin sensitizer.

Lactic acid:
Test Type: Buehler Test
Routes of exposure: Skin contact
Species: Guinea pig
Result: negative
Remarks: Based on data from similar materials

Sodium hydroxide:
Test Type: Human repeat insult patch test (HRIPT)
Routes of exposure: Skin contact
Result: negative
SAFETY DATA SHEET

Orbifloxacin Liquid Formulation

Version 3.3   Revision Date: 01.10.2020   SDS Number: 785435-00011   Date of last issue: 13.09.2019   Date of first issue: 28.06.2016

Germ cell mutagenicity
Not classified based on available information.

Components:

Orbifloxacin:
Genotoxicity in vitro:
- Test Type: Bacterial reverse mutation assay (AMES)
  Result: equivocal

  Test Type: Mouse Lymphoma
  Result: positive

  Test Type: Chromosomal aberration
  Test system: Human lymphocytes
  Result: positive

Genotoxicity in vivo:
- Test Type: Micronucleus test
  Species: Mouse
  Cell type: Bone marrow
  Application Route: Intraperitoneal injection
  Result: negative

  Test Type: unscheduled DNA synthesis assay
  Species: Rat
  Cell type: Liver cells
  Application Route: Oral
  Result: negative

Germ cell mutagenicity - Assessment: Weight of evidence does not support classification as a germ cell mutagen.

Lactic acid:
Genotoxicity in vitro:
- Test Type: Bacterial reverse mutation assay (AMES)
  Method: OECD Test Guideline 471
  Result: negative
  Remarks: Based on data from similar materials

  Test Type: In vitro mammalian cell gene mutation test
  Method: OECD Test Guideline 476
  Result: negative
  Remarks: Based on data from similar materials

  Test Type: Chromosome aberration test in vitro
  Method: OECD Test Guideline 473
  Result: negative
  Remarks: Based on data from similar materials

Carcinogenicity
Not classified based on available information.

Components:

Orbifloxacin:
Species: Rat
### SAFETY DATA SHEET

**Orbifloxacin Liquid Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
</table>

**Application Route**: Oral  
**Exposure time**: 2 Years  
**NOAEL**: 200 mg/kg body weight  
**Result**: negative

**Species**: Mouse  
**Application Route**: Oral  
**Exposure time**: 2 Years  
**NOAEL**: 200 mg/kg body weight  
**Result**: negative

### Lactic acid:

**Species**: Rat  
**Application Route**: Ingestion  
**Exposure time**: 2 Years  
**Result**: negative

**Remarks**: Based on data from similar materials

### Reproductive toxicity

Suspected of damaging the unborn child.

### Components:

#### Orbifloxacin:

**Effects on fertility**

- **Test Type**: Two-generation reproduction toxicity study  
- **Species**: Rat  
- **Application Route**: Oral  
- **General Toxicity Parent**: NOAEL: 50 mg/kg body weight  
- **Early Embryonic Development**: NOAEL: 50 mg/kg body weight  
- **Result**: No adverse effects.

**Effects on fetal development**

- **Test Type**: Embryo-fetal development  
- **Species**: Rat  
- **Application Route**: Oral  
- **Embryo-fetal toxicity**: LOAEL: 333 mg/kg body weight  
- **Result**: No teratogenic effects, embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

- **Test Type**: Embryo-fetal development  
  **Species**: Rabbit  
  **Application Route**: Oral  
  **General Toxicity Maternal**: NOAEL: 20 mg/kg body weight  
  **Embryo-fetal toxicity**: NOAEL: 60 mg/kg body weight  
  **Result**: No effects on early embryonic development, embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, Reduced maternal body weight gain.

- **Test Type**: Development  
  **Species**: Dog  
  **Application Route**: Oral  
  **Developmental Toxicity**: LOAEL: 2.5 mg/kg body weight
Result: Effects on postnatal development, Skeletal malformations.

Reproductive toxicity - Assessment:
Some evidence of adverse effects on development, based on animal experiments.

Lactic acid:
Effects on fetal development:
- Test Type: Embryo-fetal development
  - Species: Mouse
  - Application Route: Ingestion
  - Result: negative

STOT-single exposure
Not classified based on available information.

STOT-repeated exposure
May cause damage to organs (Eye) through prolonged or repeated exposure if swallowed.

Product:
- Target Organs: Eye
- Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Product:
- Species: Dog
- NOAEL: 22.5 mg/kg
- LOAEL: 37.5 mg/kg
- Application Route: Oral
- Exposure time: 30 Days
- Symptoms: Gastrointestinal disturbance

- Species: Dog
- LOAEL: 75 mg/kg
- Application Route: Oral
- Exposure time: 10 Days
- Symptoms: Salivation, Gastrointestinal disturbance, Vomiting

- Species: Cat
- LOAEL: 45 mg/kg
- Application Route: Oral
- Exposure time: 30 Days
- Target Organs: Eye
- Symptoms: Salivation, Lachrymation, Gastrointestinal disturbance, Liver disorders

Components:

Orbifloxacin:
- Species: Rat
- NOAEL: 20 mg/kg
- LOAEL: 80 mg/kg
### Orbifloxacin Liquid Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Application Route</th>
<th>Oral</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exposure time</td>
<td>3 Months</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Testis, Liver, Kidney, spleen</td>
</tr>
</tbody>
</table>

**Species**: Mouse  
**NOAEL**: 80 mg/kg  
**LOAEL**: 250 mg/kg  
**Application Route**: Oral  
**Exposure time**: 3 Months

<table>
<thead>
<tr>
<th>Species</th>
<th>Juvenile dog</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>50 mg/kg</td>
</tr>
<tr>
<td>LOAEL</td>
<td>250 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>14 Days</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Heart, Bone</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Gastrointestinal disturbance</td>
</tr>
<tr>
<td>Remarks</td>
<td>mortality observed</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Juvenile dog</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>2 mg/kg</td>
</tr>
<tr>
<td>LOAEL</td>
<td>3 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>90 Days</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Bone</td>
</tr>
<tr>
<td>Remarks</td>
<td>No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Dog</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>37.5 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>30 Days</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Cat</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>7.5 mg/kg</td>
</tr>
<tr>
<td>LOAEL</td>
<td>22.5 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>1 Months</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Gastrointestinal disturbance</td>
</tr>
</tbody>
</table>

**Lactic acid**

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>&gt; 100 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Ingestion</td>
</tr>
<tr>
<td>Exposure time</td>
<td>13 Weeks</td>
</tr>
<tr>
<td>Remarks</td>
<td>Based on data from similar materials</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOAEL</td>
<td>886 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Skin contact</td>
</tr>
<tr>
<td>Exposure time</td>
<td>13 Weeks</td>
</tr>
</tbody>
</table>

**Aspiration toxicity**

Not classified based on available information.
Experience with human exposure

Components:

Orbifloxacin:
Ingestion: Symptoms: central nervous system effects, Gastrointestinal disturbance, liver function change, anaphylaxis, Rash
Remarks: May cause photosensitization.

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Lactic acid:
Toxicity to fish: LC50 (Danio rerio (zebra fish)): > 100 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: Based on data from similar materials

Toxicity to algae/aquatic plants: ErC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

NOEC (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

Toxicity to microorganisms: EC50: > 10 - 100 mg/l
Exposure time: 3 h
Method: OECD Test Guideline 209
Remarks: Based on data from similar materials

Persistence and degradability

Components:

Lactic acid:
Biodegradability: Result: Not readily biodegradable.
Remarks: Based on data from similar materials
Bioaccumulative potential

Components:

Lactic acid:
Partition coefficient: n-octanol/water : log Pow: -0.62

Mobility in soil
No data available

Other adverse effects
No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG
Not regulated as a dangerous good

IATA-DGR
Not regulated as a dangerous good

IMDG-Code
Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

Domestic regulation

NOM-002-SCT
Not regulated as a dangerous good

Special precautions for user
Not applicable

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Federal Law for the control of chemical precursors, essential chemical products and machinery for producing capsules, tablets and pills. : Not applicable

The ingredients of this product are reported in the following inventories:

AICS : not determined
SAFETY DATA SHEET

Orbifloxacin Liquid Formulation

Version 3.3
Revision Date: 01.10.2020
SDS Number: 785435-00011
Date of last issue: 13.09.2019
Date of first issue: 28.06.2016

SECTION 16. OTHER INFORMATION

Full text of other abbreviations
ACGIH: USA. ACGIH Threshold Limit Values (TLV)
NOM-010-STPS-2014: Mexico. Norm NOM-010-STPS-2014 on Chemicals Polluting the Work Environment - Identification, Assessment and Control - Appendix 1 Occupational Exposure Limits
ACGIH / C: Ceiling limit
NOM-010-STPS-2014 / VLE-P: Ceiling value


Revision Date: 01.10.2020
The information is considered as correct, but not exhaustive, and will be used only as a guide, which is based in the current knowledge of the substance or mixture, and is applicable to proper safety precautions for the product.

MX / Z8